Neurocrine Biosciences
NBIX
#1452
Rank
C$20.75 B
Marketcap
C$204.15
Share price
-0.19%
Change (1 day)
5.78%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): C$9.82

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$9.85. In 2025 the company made an earnings per share (EPS) of C$6.73 an increase over its 2024 EPS that were of C$4.72.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$9.8245.76%
2025C$6.7342.6%
2024C$4.7233.07%
2023C$3.5557.76%
2022C$2.2569.47%
2021C$1.33-78.21%
2020C$6.09990%
2019C$0.5681.82%
2018C$0.31-113.5%
2017C-$2.280.62%
2016C-$2.2657.28%
2015C-$1.4425.61%
2014C-$1.1518.84%
2013C-$0.96-1085.71%
2012C$0.09781

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
C$1.06-89.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$4.99-49.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$41.76 323.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C$1.05-89.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.84-128.79%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$6.75-31.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
C-$10.55-207.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.62-73.39%๐Ÿ‡ฌ๐Ÿ‡ง UK